Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa
  • Amsterdam
  • Berlin
  • Brussels
  • Copenhagen
  • Danske Bank
  • Denmark
  • DFDS
  • DSV
  • Faroe Islands
  • Greenland
  • Helsinki
  • LEGO
  • Mærsk
  • Novo Nordisk
  • Ørsted
  • Oslo
  • Riga
  • Stockholm
  • Tallinn
  • Vestas Wind Systems
  • Vilnius
  • Warsaw
Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa

Browsing Tag

cardiovascular events

10 posts
NNovo Nordisk
Novo Nordisk ziltivekimab heart drug fails phase 3 trial
Read More

Novo Nordisk ziltivekimab heart drug fails phase 3 trial

  • 2026-08-04
Novo Nordisk announced Friday that its experimental heart drug ziltivekimab failed to reduce major adverse cardiovascular events in…
NNovo Nordisk
Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Read More

Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial

  • 2026-07-31
Novo Nordisk’s monoclonal antibody (mAb) designed to reduce the risk of major adverse cardiovascular events (MACE) in patients…
NNovo Nordisk
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Read More

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

  • 2026-07-31
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
NNovo Nordisk
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Read More

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

  • 2026-07-31
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
NNovo Nordisk
Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
Read More

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026

  • 2026-06-07
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 7, 2026 /PRNewswire/ — Novo Nordisk today announced Wegovy® (semaglutide) tablets 25…
NNovo Nordisk
Novo Nordisk launches Wegovy pill in UAE, its first global market
Read More

Novo Nordisk launches Wegovy pill in UAE, its first global market

  • 2026-06-03
Novo Nordisk launched its Wegovy weight loss pill in the United Arab Emirates on Wednesday, making the Gulf…
NNovo Nordisk
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
Read More

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

  • 2026-06-03
Novo Nordisk A/S Novo Nordisk launches Wegovy® pill in the United Arab Emirates today Wegovy® pill is indicated…
NNovo Nordisk
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
Read More

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

  • 2026-06-03
Novo Nordisk A/S Novo Nordisk launches Wegovy® pill in the United Arab Emirates today Wegovy® pill is indicated…
NNovo Nordisk
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
Read More

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

  • 2026-05-22
Novo Nordisk A/S With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is…
NNovo Nordisk
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
Read More

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

  • 2026-05-22
Novo Nordisk A/S With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is…
Denmark
www.europesays.com